No Data
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma
Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial
3 Best Stocks to Buy Today, According to Top Analysts, 6/9/2026
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)
Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug
Express News | Verastem - Initiates Phase 2 Target-D 202 Trial for Advanced Nsclc